Ziccum AB (publ) ('Ziccum') has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies to commence a Feasibility study regarding LaminarPace for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s). mRNA is a top strategic priority for Ziccum, and in March 2023 it announced positive results in its in-house project, drying active mRNA in LNP formulation.
Ziccum AB (publ) ('Ziccum') has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies. This new agreement is for a fully financed Feasibility study, formulating and drying mRNA/LNP materials with LaminarPace ambient drying.
The Evaluation agreement signing is a milestone achievement in one of the highlighted partnering dialogues in Ziccum's regularly updated Project Portfolio overview. Since 2022, following new leadership and a significant strategic refocus, Ziccum has successfully pursued a dynamic partnering agenda, creating a pipeline of industrial dialogues.
The agreement is the result of keen interest in the LaminarPace technology to generate dry powder materials in mRNA/LNP technology development. This is based on successful results on the mRNA/LNP platform for LaminarPace, an entirely new drying technology making dry powder biopharmaceuticals possible. The Feasibility study is expected to start in May 2023.
CEO Ann Gidner: "We are delighted to sign this agreement with such an important, leading mRNA player and to continue work in this highly interesting field. For us at Ziccum this collaboration confirms the strong interest for our novel technology, enabling thermostable biopharmaceuticals in general and the most fragile mRNA/LNP in particular, and it confirms our outreach in the international Pharma industry. We are indeed excited to move forward."
Chairman Fredrik Sjövall: "This agreement is a breakthrough for Ziccum and a strong acknowledgement of what our technology can offer the key players in this industry. It also confirms our new strategy, business model and capability to move partnering dialogues forward, thanks to the combination of good leadership and strong technical data being generated in well-defined internal trials."
For more information about Ziccum, please contact:
Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141
Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75
Ziccum's Certified Adviser is Erik Penser Bank AB
Follow us on https://eucaps.com/ziccum
About Ziccum
Ziccum is developing LaminarPaceTM, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.
This information is information that Ziccum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-09 17:50 CEST.
